| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$249,162 ) |
| | 2025 | 2024 | FZATA INC | 1450 S ROLLING RD | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | UG3NS135350 | A novel oral immunotherapy for chronic visceral pain of irritable bowel syndrome | 000 | 1 | NIH | 12/24/2024 | -$36,871 |
| | 2025 | 2023 | FZATA INC | 1450 S ROLLING RD | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44DK129133 | Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track) | 000 | 3 | NIH | 9/9/2025 | $0 |
| | 2025 | 2023 | FZATA INC | 1450 S ROLLING RD | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44AI136176 | A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II) | 000 | 4 | NIH | 5/15/2025 | $0 |
| | 2025 | 2023 | FZATA INC | 1450 S ROLLING RD | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44AI155277 | A Yeast-based Immunotherapy against Clostridioides difficile infection | 000 | 4 | NIH | 4/16/2025 | $0 |
| | 2025 | 2022 | FZATA INC | 1450 S ROLLING RD | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R01AI132207 | A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection | 000 | 6 | NIH | 10/1/2024 | -$212,291 |
| | 2025 | 2022 | FZATA INC | 1450 S ROLLING RD | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R01AI132207 | A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection | 001 | 6 | NIH | 1/22/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $2,128,420 ) |
| | 2024 | 2024 | FZATA INC | 1450 S ROLLING RD | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | UG3NS135350 | A novel oral immunotherapy for chronic visceral pain of irritable bowel syndrome | 000 | 1 | NIH | 8/29/2024 | $2,128,420 |
| | 2024 | 2023 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44AI155277 | A Yeast-based Immunotherapy against Clostridioides difficile infection | 000 | 4 | NIH | 2/16/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $2,769,631 ) |
| | 2023 | 2023 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44AI136176 | A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II) | 000 | 4 | NIH | 8/10/2023 | $923,175 |
| | 2023 | 2023 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44DK129133 | Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track) | 000 | 3 | NIH | 4/14/2023 | $950,520 |
| | 2023 | 2023 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44AI155277 | A Yeast-based Immunotherapy against Clostridioides difficile infection | 001 | 4 | NIH | 9/13/2023 | $0 |
| | 2023 | 2023 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44AI155277 | A Yeast-based Immunotherapy against Clostridioides difficile infection | 000 | 4 | NIH | 10/24/2022 | $906,503 |
| | 2023 | 2022 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R01AI132207 | A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection | 000 | 6 | NIH | 6/26/2023 | $0 |
| | 2023 | 2021 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44DK129133 | Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track) | 001 | 1 | NIH | 5/15/2023 | -$10,567 |
|
| Issue Date FY: 2022 ( Subtotal = $3,784,946 ) |
| | 2022 | 2022 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44AI136176 | A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II) | 000 | 3 | NIH | 8/11/2022 | $988,488 |
| | 2022 | 2022 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44DK129133 | Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track) | 000 | 2 | NIH | 4/15/2022 | $855,001 |
| | 2022 | 2022 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44AI155277 | A Yeast-based Immunotherapy against Clostridioides difficile infection | 001 | 3 | NIH | 9/26/2022 | $0 |
| | 2022 | 2022 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44AI155277 | A Yeast-based Immunotherapy against Clostridioides difficile infection | 000 | 3 | NIH | 11/5/2021 | $932,749 |
| | 2022 | 2022 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R01AI132207 | A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection | 000 | 6 | NIH | 6/2/2022 | $1,008,708 |
|
| Issue Date FY: 2021 ( Subtotal = $1,974,020 ) |
| | 2021 | 2021 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44AI136176 | A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II) | 000 | 2 | NIH | 7/30/2021 | $999,996 |
| | 2021 | 2021 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R01AI132207 | A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection | 000 | 5 | NIH | 6/16/2021 | $167,253 |
| | 2021 | 2021 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44DK129133 | Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track) | 001 | 1 | NIH | 5/5/2021 | $0 |
| | 2021 | 2021 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44AI155277 | A Yeast-based Immunotherapy against Clostridioides difficile infection | 000 | 2 | NIH | 3/30/2021 | $537,623 |
| | 2021 | 2021 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44AI155277 | A Yeast-based Immunotherapy against Clostridioides difficile infection | 001 | 2 | NIH | 4/23/2021 | $16,732 |
| | 2021 | 2021 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44AI155277 | A Yeast-based Immunotherapy against Clostridioides difficile infection | 003 | 2 | NIH | 9/27/2021 | $0 |
| | 2021 | 2021 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44DK129133 | Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track) | 000 | 1 | NIH | 4/27/2021 | $252,416 |
| | 2021 | 2020 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44AI155277 | A Yeast-based Immunotherapy against Clostridioides difficile infection | 002 | 1 | NIH | 9/15/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,704,804 ) |
| | 2020 | 2020 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44AI155277 | A Yeast-based Immunotherapy against Clostridioides difficile infection | 000 | 1 | NIH | 7/20/2020 | $169,461 |
| | 2020 | 2020 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R01AI132207 | A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection | 003 | 4 | NIH | 8/11/2020 | $2,154,339 |
| | 2020 | 2020 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R44AI155277 | A Yeast-based Immunotherapy against Clostridioides difficile infection | 001 | 1 | NIH | 7/21/2020 | $0 |
| | 2020 | 2019 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R01AI132207 | A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection | 002 | 3 | NIH | 7/29/2020 | $229,186 |
| | 2020 | 2018 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R43AI136176 | A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridium difficile Infection | 000 | 1 | NIH | 5/12/2020 | $0 |
| | 2020 | 2018 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R01AI132207 | A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection | 001 | 2 | NIH | 7/29/2020 | $79,403 |
| | 2020 | 2018 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R43AI136108 | Novel Immunotherapies for Comorbidity of Clostridium difficile and Inflammatory Bowel Disease | 000 | 1 | NIH | 5/12/2020 | $0 |
| | 2020 | 2017 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R01AI132207 | A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection | 000 | 1 | NIH | 7/29/2020 | $72,415 |
|
| Issue Date FY: 2019 ( Subtotal = $1,909,432 ) |
| | 2019 | 2019 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R01AI132207 | A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection | 001 | 3 | NIH | 6/3/2019 | $1,909,432 |
| | 2019 | 2018 | FZATA INC | 1448 S ROLLING RD STE 120 | HALETHORPE | MD | 21227-3831 | BALTIMORE | USA | R01AI132207 | A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection | 000 | 2 | NIH | 3/1/2019 | $0 |
| | 2019 | 2017 | FZATA INC | 1450 S ROLLING RD STE 4101 | HALETHORPE | MD | 21227-3863 | BALTIMORE | USA | R43AI129044 | A Yeast based Immunotherapy against Clostridium difficile Infection | 000 | 1 | NIH | 5/21/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,485,487 ) (Continued on the next page) |
| | 2018 | 2018 | FZATA INC | 1448 S ROLLING RD STE 120 | HALETHORPE | MD | 21227-3831 | BALTIMORE | USA | R43AI136176 | A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridium difficile Infection | 000 | 1 | NIH | 1/20/2018 | $168,931 |
| | 2018 | 2018 | FZATA INC | 1448 S ROLLING RD STE 120 | HALETHORPE | MD | 21227-3831 | BALTIMORE | USA | R43AI136108 | Novel Immunotherapies for Comorbidity of Clostridium difficile and Inflammatory Bowel Disease | 001 | 1 | NIH | 2/1/2018 | $224,999 |
| | 2018 | 2018 | FZATA INC | 1448 S ROLLING RD STE 120 | HALETHORPE | MD | 21227-3831 | BALTIMORE | USA | R43AI136108 | Novel Immunotherapies for Comorbidity of Clostridium difficile and Inflammatory Bowel Disease | 001 | 1 | NIH | 2/1/2018 | -$224,999 |
| | 2018 | 2018 | FZATA INC | 1448 S ROLLING RD STE 120 | HALETHORPE | MD | 21227-3831 | BALTIMORE | USA | R43AI136176 | A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridium difficile Infection | 001 | 1 | NIH | 1/31/2018 | -$168,931 |
|
